Hsa-miR-425-5p promotes tumor growth and metastasis by activating the CTNND1-mediated β-catenin pathway and EMT in colorectal cancer. Issue 15 (2nd August 2020)

• Record Type: Journal Article
• Authors: Liu, Dingsheng; Zhang, Hong; Cui, Mingming; Chen, Chunsheng; Feng, Yong
• Is Part Of: Cell cycle. Volume 19:Issue 15(2020)
• Page Start: 1917
• Page End: 1927
• Publication Date: 2020-08-02
• Subjects: Colorectal cancer -- miR-425-5p -- catenin-δ1 (CTNND1) -- β-catenin pathway -- tumor growth -- metastasis; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2020.1783058
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Colorectal cancer (CRC) is a common malignancy with high mortality. However, the roles of miR-425-5p and its underlying mechanism in CRC remain unknown. Here, RT-qPCR confirmed that miR-425-5p expression was increased by miR-425-5p mimic in SW480 cells and decreased by miR-425-5p inhibitor in LOVO cells. CCK-8, flow cytometry, wound healing and transwell assays revealed that the increased miR-425-5p promoted cell viability, cell cycle entry, migration and invasion in CRC. Besides, miR-425-5p overexpression induced epithelial–mesenchymal transition (EMT) with upregulation of Fibronectin, N-cadherin, Vimentin, and downregulation of E-cadherin. Moreover, miR-425-5p overexpression induced c-myc, Cyclin D1 and MMP7 levels, and promoted β-catenin translocation to the nucleus. Knockdown of miR-425-5p exerted opposite effects. Luciferase reporter assay indicated that miR-425-5p directly targeted CTNND1. Overexpression of miR-425-5p repressed CTNND1 expression at mRNA and protein levels. Silencing of CTNND1 had the inhibitory effect of miR-425-5p inhibitor on cell proliferation, migration, invasion, EMT, and the activation of β-catenin signaling pathway. Furthermore, miR-425-5p promoted tumor growth and metastasis in vivo. In conclusion, miR-425-5p may promote tumorigenesis and metastasis through activating CTNND1-mediated β-catenin pathway, which may provide therapeutic targets for human CRC.